<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-SHM-16666</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-3029</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>Растворимые факторы макрофагов человека способны ингибировать TGF-β-индуцированную дифференцировку фибробластов легких</article-title><trans-title-group xml:lang="en"><trans-title>Soluble human macrophage factors are able to inhibit TGF-β-induced differentiation of lung fibroblasts</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максимова Александра Александровна - к.м.н., младший научный сотрудник лаборатории клеточной иммунотерапии,</p><p>630099, г. Новосибирск, ул. Ядринцевская, 14</p></bio><bio xml:lang="en"><p>Aleksandra A. Maksimova - PhD (Medicine), Junior Research Associate, Laboratory of Cellular Immunotherapy,</p><p>14 Yadrintsevskaya St Novosibirsk 630099</p></bio><email xlink:type="simple">parkinson.dses@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шевела</surname><given-names>Е. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Shevela</surname><given-names>E. Ya.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., ведущий научный сотрудник лаборатории клеточной иммунотерапии,</p><p>630099, г. Новосибирск, ул. Ядринцевская, 14</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Leading Research Associate, Laboratory of Cellular Immunotherapy, </p><p>14 Yadrintsevskaya St Novosibirsk 630099</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сахно</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sakhno</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.б.н., старший научный сотрудник лаборатории клеточной иммунотерапии,</p><p>630099, г. Новосибирск, ул. Ядринцевская, 14</p></bio><bio xml:lang="en"><p>PhD (Biology), Senior Research Associate, Laboratory of Cellular Immunotherapy,</p><p>14 Yadrintsevskaya St Novosibirsk 630099</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Fundamental and Clinical Immunology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>18</day><month>07</month><year>2024</year></pub-date><volume>26</volume><issue>4</issue><fpage>649</fpage><lpage>656</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Максимова А.А., Шевела Е.Я., Сахно Л.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Максимова А.А., Шевела Е.Я., Сахно Л.В.</copyright-holder><copyright-holder xml:lang="en">Maksimova A.A., Shevela E.Y., Sakhno L.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/3029">https://www.mimmun.ru/mimmun/article/view/3029</self-uri><abstract><p>Макрофаги являются ключевыми клетками-регуляторами фиброгенеза и благодаря своей пластичности и гетерогенности способны оказывать как про-, так и антифиброгенное действие. В некоторых работах был продемонстрирован антифиброгенный потенциал макрофагов в отношении фибробластов дермы, однако влияние макрофагов на функции фибробластов легких остается неисследованным. Таким образом, целью данного исследования являлось изучение влияния кондиционных сред макрофагов человека, дифференцированных M-CSF/GM-CSF и далее поляризованных дексаметазоном/неполяризованных на TGF-β-индуцированную дифференцировку фибробластов легких. Макрофаги генерировали из моноцитов периферической крови условно здоровых доноров в присутствии M-CSF или GM-CSF в течение 7 дней. На 5-й день добавляли дексаметазон с целью получения поляризованных макрофагов M-M(Dex) и GM-M(Dex), которые сравнивали с неполяризованными M-M0 и GM-M0, к которым не добавляли дексаметазон. Далее собирали кондиционную среду макрофагов указанных подтипов, которую тестировали по способности ингибировать дифференцировку фибробластов легких (клеточная линия HLF210). Для этого к культурам фибробластов одномоментно добавляли TGF-β (индуцирующий фактор дифференцировки) и кондиционную среду макрофагов. Дифференцировку оценивали по уровню экспрессии маркера миофибробластов α-гладкомышечного актина (α-SMA) и продукции белка внеклеточного матрикса – коллагена I типа. Анализ α-SMA был выполнен при помощи проточной цитометрии. Содержание коллагена I типа определяли иммуноферментным методом. Оценку экспрессии α-SMA проводили с использованием 3D-культур фибробластов, поскольку полученные нами данные демонстрируют, что при стандартном культивировании происходит спонтанная активация фибробластов, тогда как в 3D-культурах количество α-SMA-позитивных клеток значительно меньше, что свидетельствует о более физиологичном росте клеток. Кондиционные среды дексаметазон-поляризованных макрофагов, независимо от дифференцировочного стимула, не влияли значимо на экспрессию α-SMA, а также уровень продукции коллагена I типа клетками HLF210. Напротив, растворимые факторы М-М0 оказывали выраженный ингибирующий эффект, приводя к снижению количества фибробластов, экспрессирующих маркер миофибробластов, а также к снижению содержания коллагена I типа в исследуемых культурах фибробластов. При этом GM-M0 не обладали таковым эффектом и, подобно поляризованным макрофагам, не ингибировали дифференцировку фибробластов легких. В целом, полученные результаты свидетельствуют о возможном антифиброгенном потенциале М-М0 макрофагов. При этом отсутствие такового эффекта в GM-M0 макрофагах свидетельствует о важном вкладе дифференцировочного фактора в формирование антифиброгенного фенотипа макрофагов.</p></abstract><trans-abstract xml:lang="en"><p>Macrophages are key regulatory cells of fibrogenesis. They can have pro- or antifibrotic activity due to their plasticity and heterogeneity. Some studies have shown the antifibrotic effect of macrophages on dermal fibroblasts, but the effect of macrophages on the lung fibroblast functions remains unexplored. Therefore, the purpose of this study was to examine the influence of conditioned media of human macrophage differentiated by M-CSF/GM-CSF and further dexamethasone polarized/unpolarized on the TGF-β-induced lung fibroblast differentiation. Macrophages were derived from peripheral blood monocytes of healthy donors. Monocytes were differentiated by M-CSF or GM-CSF for 7 days. On day 5, dexamethasone was added to generation of polarized macrophages M-M(Dex) and GM-M(Dex). Polarized macrophages were compared with non-polarized M-M0 and GM-M0, to which dexamethasone was not added. Next, the conditioned medium of these macrophage subtypes was collected and tested for inhibition the lung fibroblast differentiation (HLF210 cell line). To do this, TGF-β (inducing differentiation factor) and conditioned macrophage medium were added to fibroblast cultures. Effectiveness of differentiation was estimated by the expression of the myofibroblast marker, α-smooth muscle actin (α-SMA), and the production of extracellular matrix protein, collagen I. The expression of α-SMA was determined using flow cytometry. The concentration of collagen I was measured by ELISA. Since our data indicates that spontaneous activation of fibroblasts occurs during standard cultivation, the α-SMA expression was investigated in 3D culture of fibroblasts. Notably, the content of α-SMA-positive cells in 3D cultures was significantly reduced, indicating more physiological growth cells. Regardless of the differentiation stimulus, the conditioned media of dexamethasone-polarized macrophages do not affect the level of collagen I production or the α-SMA expression. On the contrary, M-M0 showed a strong inhibitory effect that reduced the amount of collagen I in the fibroblast cultures and the expression of marker myofibroblasts by fibroblasts. Interesting, GM-M0 had no such effect and did not prevent lung fibroblast differentiation like polarized cells. Taken together, the findings suggest that M-M0 macrophages may have antifibrotic properties. Furthermore, the lack of this effect in GM-M0 macrophages indicates that the differentiation factor plays a significant role in the development of the antifibrotic macrophage phenotype.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>макрофаги</kwd><kwd>фибробласты</kwd><kwd>кондиционные среды</kwd><kwd>антифиброгенная активность</kwd><kwd>коллаген</kwd><kwd>α-гладкомышечный актин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>macrophages</kwd><kwd>fibroblasts</kwd><kwd>conditioned media</kwd><kwd>antifibrotic activity</kwd><kwd>collagen</kwd><kwd>α-smooth actin</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках гранта РНФ № 23-25-00349, https://rscf.ru/project/23-25-00349.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bagalad B.S., Mohan Kumar K.P., Puneeth H.K. Myofibroblasts: Master of disguise. J. Oral Maxillofac. Pathol., 2017, Vol. 21, no. 3, pp. 462-463.</mixed-citation><mixed-citation xml:lang="en">Bagalad B.S., Mohan Kumar K.P., Puneeth H.K. Myofibroblasts: Master of disguise. J. Oral Maxillofac. Pathol., 2017, Vol. 21, no. 3, pp. 462-463.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Brennan P.N., MacMillan M., Manship T., Moroni F., Glover A., Graham C., Semple S., Morris D.M., Fraser A.R., Pass C., McGowan N.W.A., Turner M.L., Lachlan N., Dillon J.F., Campbell J.D.M., Fallowfield J.A., Forbes S.J. Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH). BMJ Open, 2021, Vol. 11, no. 11, e053190. doi: 10.1136/bmjopen-2021-053190.</mixed-citation><mixed-citation xml:lang="en">Brennan P.N., MacMillan M., Manship T., Moroni F., Glover A., Graham C., Semple S., Morris D.M., Fraser A.R., Pass C., McGowan N.W.A., Turner M.L., Lachlan N., Dillon J.F., Campbell J.D.M., Fallowfield J.A., Forbes S.J. Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH). BMJ Open, 2021, Vol. 11, no. 11, e053190. doi: 10.1136/bmjopen-2021-053190.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chang C.H., Juan Y.H., Hu H.C., Kao K.C., Lee C.S. Reversal of lung fibrosis: an unexpected finding in survivor of acute respiratory distress syndrome. QJM, 2018, Vol. 111, no. 1, pp. 47-48.</mixed-citation><mixed-citation xml:lang="en">Chang C.H., Juan Y.H., Hu H.C., Kao K.C., Lee C.S. Reversal of lung fibrosis: an unexpected finding in survivor of acute respiratory distress syndrome. QJM, 2018, Vol. 111, no. 1, pp. 47-48.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Koudelka A., Cechova V., Rojas M., Mitash N., Bondonese A., St Croix C., Ross M.A., Freeman B.A. Fatty acid nitroalkene reversal of established lung fibrosis. Redox Biology, 2022, Vol. 50, 102226. doi: 10.1016/j.redox.2021.102226.</mixed-citation><mixed-citation xml:lang="en">Koudelka A., Cechova V., Rojas M., Mitash N., Bondonese A., St Croix C., Ross M.A., Freeman B.A. Fatty acid nitroalkene reversal of established lung fibrosis. Redox Biology, 2022, Vol. 50, 102226. doi: 10.1016/j.redox.2021.102226.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Landry N.M., Rattan S.G., Dixon I.M.C. An improved method of maintaining primary murine cardiac fibroblasts in two-dimensional cell culture. Sci. Rep., 2019, no. 9, 12889. doi: 10.1038/s41598-019-49285-9.</mixed-citation><mixed-citation xml:lang="en">Landry N.M., Rattan S.G., Dixon I.M.C. An improved method of maintaining primary murine cardiac fibroblasts in two-dimensional cell culture. Sci. Rep., 2019, no. 9, 12889. doi: 10.1038/s41598-019-49285-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Machahua C., Vicens-Zygmunt V., Ríos-Martín J., Llatjós R., Escobar-Campuzano I., Molina-Molina M., Montes-Worboys A. Collagen 3D matrices as a model for the study of cell behavior in pulmonary fibrosis. Exp. Lung Res., 2022, Vol. 48, no. 3, pp. 126-136.</mixed-citation><mixed-citation xml:lang="en">Machahua C., Vicens-Zygmunt V., Ríos-Martín J., Llatjós R., Escobar-Campuzano I., Molina-Molina M., Montes-Worboys A. Collagen 3D matrices as a model for the study of cell behavior in pulmonary fibrosis. Exp. Lung Res., 2022, Vol. 48, no. 3, pp. 126-136.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Meng X.M., Nikolic-Paterson D.J., Lan H.Y. TGF-β: the master regulator of fibrosis. Nat. Rev. Nephrol., 2016, Vol. 12, no. 6, pp. 325-338.</mixed-citation><mixed-citation xml:lang="en">Meng X.M., Nikolic-Paterson D.J., Lan H.Y. TGF-β: the master regulator of fibrosis. Nat. Rev. Nephrol., 2016, Vol. 12, no. 6, pp. 325-338.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mikkelsen L.F., Rubak S. Reversible lung fibrosis in a 6-year-old girl after long term nitrofurantoin treatment. BMC Pulm. Med., 2020, Vol. 20, 313. doi: 10.1186/s12890-020-01353-x.</mixed-citation><mixed-citation xml:lang="en">Mikkelsen L.F., Rubak S. Reversible lung fibrosis in a 6-year-old girl after long term nitrofurantoin treatment. BMC Pulm. Med., 2020, Vol. 20, 313. doi: 10.1186/s12890-020-01353-x.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., Gordon S., Hamilton J.A., Ivashkiv L.B., Lawrence T., Locati M., Mantovani A., Martinez F.O., Mege J.L., Mosser D.M., Natoli G., Saeij J.P., Schultze J.L., Shirey K.A., Sica A., Suttles J., Udalova I., van Ginderachter J.A., Vogel S.N., Wynn T.A. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 2014, Vol. 41, no. 1, pp. 14-20.</mixed-citation><mixed-citation xml:lang="en">Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., Gordon S., Hamilton J.A., Ivashkiv L.B., Lawrence T., Locati M., Mantovani A., Martinez F.O., Mege J.L., Mosser D.M., Natoli G., Saeij J.P., Schultze J.L., Shirey K.A., Sica A., Suttles J., Udalova I., van Ginderachter J.A., Vogel S.N., Wynn T.A. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 2014, Vol. 41, no. 1, pp. 14-20.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sapudom J., Karaman S., Mohamed W.K.E., Garcia-Sabaté A., Quartey B.C., Teo J.C.M. 3D in vitro M2 macrophage model to mimic modulation of tissue repair. NPJ Regen. Med., 2021, no. 6, 83. doi: 10.1038/s41536-021-00193-5.</mixed-citation><mixed-citation xml:lang="en">Sapudom J., Karaman S., Mohamed W.K.E., Garcia-Sabaté A., Quartey B.C., Teo J.C.M. 3D in vitro M2 macrophage model to mimic modulation of tissue repair. NPJ Regen. Med., 2021, no. 6, 83. doi: 10.1038/s41536-021-00193-5.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sari E., He C., Margaroli C. Plasticity towards rigidity: a macrophage conundrum in pulmonary fibrosis. Int. J. Mol. Sci., 2022, Vol. 23, no. 19, 11443. doi: 10.3390/ijms231911443.</mixed-citation><mixed-citation xml:lang="en">Sari E., He C., Margaroli C. Plasticity towards rigidity: a macrophage conundrum in pulmonary fibrosis. Int. J. Mol. Sci., 2022, Vol. 23, no. 19, 11443. doi: 10.3390/ijms231911443.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Song E., Ouyang N., Hörbelt M., Antus B., Wang M., Exton M.S. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell. Immunol., 2000, Vol. 204, no. 1, pp. 19-28.</mixed-citation><mixed-citation xml:lang="en">Song E., Ouyang N., Hörbelt M., Antus B., Wang M., Exton M.S. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell. Immunol., 2000, Vol. 204, no. 1, pp. 19-28.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tarique A.A., Logan J., Thomas E., Holt P.G., Sly P.D., Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am. J. Respir. Cell Mol. Biol., 2015, Vol. 53, no. 5, pp. 676-688.</mixed-citation><mixed-citation xml:lang="en">Tarique A.A., Logan J., Thomas E., Holt P.G., Sly P.D., Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am. J. Respir. Cell Mol. Biol., 2015, Vol. 53, no. 5, pp. 676-688.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ullm F., Riedl P., Machado de Amorim A., Patzschke A., Weiß R., Hauschildt S., Franke K., Anderegg U., Pompe T. 3D scaffold-based macrophage fibroblast coculture model reveals IL-10 dependence of wound resolution phase. Adv. Biosyst., 2020, Vol. 4, no. 1, e1900220. doi: 10.1002/adbi.201900220.</mixed-citation><mixed-citation xml:lang="en">Ullm F., Riedl P., Machado de Amorim A., Patzschke A., Weiß R., Hauschildt S., Franke K., Anderegg U., Pompe T. 3D scaffold-based macrophage fibroblast coculture model reveals IL-10 dependence of wound resolution phase. Adv. Biosyst., 2020, Vol. 4, no. 1, e1900220. doi: 10.1002/adbi.201900220.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Xue J., Schmidt S.V., Sander J., Draffehn A., Krebs W., Quester I., de Nardo D., Gohel T.D., Emde M., Schmidleithner L., Ganesan H., Nino-Castro A., Mallmann M.R., Labzin L., Theis H., Kraut M., Beyer M., Latz E., Freeman T.C., Ulas T., Schultze J.L. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity, 2014, Vol. 40, no. 2, pp. 274-288.</mixed-citation><mixed-citation xml:lang="en">Xue J., Schmidt S.V., Sander J., Draffehn A., Krebs W., Quester I., de Nardo D., Gohel T.D., Emde M., Schmidleithner L., Ganesan H., Nino-Castro A., Mallmann M.R., Labzin L., Theis H., Kraut M., Beyer M., Latz E., Freeman T.C., Ulas T., Schultze J.L. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity, 2014, Vol. 40, no. 2, pp. 274-288.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
